Prexton Therapeutics
Developing novel small molecule therapeutics for Parkinson’s disease
Prexton Therapeutics is developing programs in Parkinson’s disease focused on targeting metabotropic glutamate receptors.
Prexton was acquired by Lundbeck in 2018.